SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.
<h4>Unlabelled</h4>SPL7013 Gel (VivaGel(®)) is a microbicide in development for prevention of HIV and HSV. This clinical study assessed retention and duration of antiviral activity following vaginal administration of 3% SPL7013 Gel in healthy women. Participants received 5 single doses o...
Guardado en:
Autores principales: | Clare F Price, David Tyssen, Secondo Sonza, Ashley Davie, Sonya Evans, Gareth R Lewis, Shirley Xia, Tim Spelman, Peter Hodsman, Thomas R Moench, Andrew Humberstone, Jeremy R A Paull, Gilda Tachedjian |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bdfe8b68946e44cf931a6d338a6ecc77 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Transdermal delivery of paeonol using cubic gel and microemulsion gel
por: Chen J, et al.
Publicado: (2011) -
Gel point determination of gellan biopolymer gel from DC electrical conductivity
por: Jahan Nusrat, et al.
Publicado: (2020) -
Rheoacoustic Gels: Tuning Mechanical and Flow Properties of Colloidal Gels with Ultrasonic Vibrations
por: Thomas Gibaud, et al.
Publicado: (2020) -
Hit-Gel: Streamlining in-gel protein digestion for high-throughput proteomics experiments
por: Corné Swart, et al.
Publicado: (2018) -
Boundaries steer the contraction of active gels
por: Matthias Schuppler, et al.
Publicado: (2016)